Abstract 1227P
Background
Assessment of HER2 status is critical for diagnosis and guiding therapy in breast cancer. However, the current immunohistochemistry-based analysis of HER2 requires tissue biopsy, is time-consuming, subjective, and semi-quantitative. This is the reason for delayed or incorrect treatment decisions and worse outcomes. To address these limitations, we developed an innovative inPROBE diagnostic device, which allows for real-time quantitative and operator-independent HER2 level determination, directly in the patient’s body.
Methods
The HER2 measurements were performed using the inPROBE device consisting of an optical sensor designed for the detection of the soluble HER2 or the anti-HER2 drug – Trastuzumab (TMAB). The in vitro inProbe testing was done on the standard HER2 protein solutions to demonstrate the device working range and the tissue accumulation of TMAB was assessed in vivo on the mouse xenograft model of a human HER2+ cancer. The device safety was confirmed on rats with a probe insertion into the mammary glands to monitor the clinical, biochemical and pathological changes.
Results
inProbe working range tested on HER2 solution was within the concentration of pg/ml – mg/ml with good linearity and selectivity toward HER2. In preclinical safety experiments, inPROBE insertion into the mammary glands did not cause any adverse clinical signs, changes in blood parameters, or histology. In alternative sets of experiments, the TMAB-inProbe proved its utility for direct detection of the anti-HER2 drug accumulating in the HER2+ tumor tissue.
Conclusions
HER2-inPROBE is a specific and sensitive sensor, allowing for rapid, quantitative analysis of HER2. Given its high adaptability, the inPROBE platform presents the potential to be used for the detection of various diseases biomarkers, without the need for tissue biopsy. The clinical trial to determine the diagnostic accuracy and safety of the inPROBE in 192 patients with early breast cancer is underway (NCT05415943).
Clinical trial identification
NCT05415943.
Editorial acknowledgement
Legal entity responsible for the study
SDS Optic.
Funding
STRATEGMED II/269364/5/NCBR/2015; EU, Horizon 2020 SME Instrument (No. 783818).
Disclosure
M. Staniszewska, M. Śmietana, M. Staniszewski: Financial interests, Institutional, Membership or affiliation: SDS Optic, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14